TrialPloS one2016

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.

Pirow Bekker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.